ProsTIC at Peter Mac is a world-leader in theranostics.
Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET scan and then a similar radioactive molecule that kills cancer cells.
Peter Mac has pioneered research globally, performing our first PSMA PET scan in 2014, and our first PSMA therapy in 2015.
The ProsTIC program has three aims:
- Accelerate clinical trial research: Expand the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high-impact need that are not currently being addressed.
- Education and Leadership: Establish a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this new technology.
- Discovery research: Further investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation.
Email: [email protected]
ProsTIC was officially launched on June 11, 2020 at Peter MacCallum Cancer Centre.